Details for New Drug Application (NDA): 216986
✉ Email this page to a colleague
NDA 216986 describes ELUCIREM, which is a drug marketed by Guerbet and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the ELUCIREM profile page.
The generic ingredient in ELUCIREM is gadopiclenol. Two suppliers are listed for this compound. Additional details are available on the gadopiclenol profile page.
The generic ingredient in ELUCIREM is gadopiclenol. Two suppliers are listed for this compound. Additional details are available on the gadopiclenol profile page.
Summary for 216986
| Tradename: | ELUCIREM |
| Applicant: | Guerbet |
| Ingredient: | gadopiclenol |
| Patents: | 3 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 216986
Generic Entry Date for 216986*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 216986
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986 | NDA | BRACCO DIAGNOSTICS INC | 0270-7015 | 0270-7015-46 | 25 VIAL, SINGLE-DOSE in 1 CASE (0270-7015-46) / 30 mL in 1 VIAL, SINGLE-DOSE |
| ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986 | NDA | BRACCO DIAGNOSTICS INC | 0270-7015 | 0270-7015-48 | 25 VIAL, SINGLE-DOSE in 1 CASE (0270-7015-48) / 50 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1.4553GM/3ML (485.1MG/ML) | ||||
| Approval Date: | Sep 21, 2022 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Sep 21, 2027 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Aug 6, 2039 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
| Patent: | ⤷ Sign Up | Patent Expiration: | Jan 17, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
